Amgen Deal History & Licensing Activity
Amgen is a large pharma headquartered in US. Over the past three years, Amgen has been involved in 9 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
4
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
Amgen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Amgen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| multiple oncology products (XGEVA, BLINCYTO, KYPROLIS) | BeiGene | Other | Approved | co development | Jul 18, 2026 |
| Aimovig | Novartis | Antibodies | Approved | co development | Jul 18, 2026 |
| Probody T-cell-engaging bispecifics (EGFR) | CytomX Therapeutics | Bispecific Antibodies | Unknown |
Amgen Pipeline Focus
Therapeutic areas and modalities where Amgen is most active based on deal history and clinical trial data.
Therapeutic Areas
Amgen Strategic Signals
Key indicators of Amgen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Amgen Clinical Pipeline
Amgen has 50 active clinical trials across 6 development phases.
2
Unknown
1
Not Applicable
1
Phase 4
14
Phase 1
14
Phase 2
18
Phase 3
See How Your Asset Matches Amgen's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Amgen Licensing & Deal Activity
Amgen is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Amgen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Amgen include Solid Tumors (11 deals and trials), Oncology (10 deals and trials), Metabolic (9 deals and trials), and Hematological Malignancies (6 deals and trials). In terms of modality, Amgen has shown particular interest in bispecific antibodies, mab, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Amgen and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Amgen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.